VJOncology Podcast

Latest Episodes:

Antibody drug conjugates in gastrointestinal cancers Nov 29, 2024

Show notes

This week’s podcast from VJOncology brings you key updates in antibody drug conjugates (ADCs) for gastrointestinal cancer. Our expert panel discusses the potential of ADCs targeting HER2, CMET, and CEACAM5 in gastric and colorectal cancers.

Hear from experts Kohei Shitara (National Cancer Center Hospital East), Yelena Janjigian (Memorial Sloan Kettering Cancer Center), John Strickler (Duke Cancer Institute), and Scott Kopetz (MD Anderson Cancer Center) as they provide an overview of the latest in ADCs for gastrointestinal cancers. Highlights include novel treatment strategies in HER2-expressing gastric cancer, findings from the DESTINY-Gastric03 and ABBV-400 trials, and the role of CEACAM5-targeting ADCs in colorectal cancer.

The post Antibody drug conjugates in gastrointestinal cancers appeared first on VJOncology.

Novel therapeutics in PD-1 refractory melanoma Nov 15, 2024

Show notes

This week’s podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison Betoff Warner (Stanford University, Stanford, CA), Andrew Furness (Royal Marsden Hospital, London, UK), Anna Di Giacomo (University Hospital of Siena, Siena, Italy), María Vieito (Vall d’Hebron Institute of Oncology, Barcelona, Spain), and Yana Najjar (UPMC Hillman Cancer Center, Pittsburgh, PA), as they share insights into cutting-edge therapies and trials.

Highlights include the FDA approval of TIL therapy in metastatic melanoma, early findings on off-the-shelf T-cell therapy, and results from the NIBIT-ML1 trial (NCT04250246) investigating a triple combination of ipilimumab, nivolumab, and ASTX727. Discover updates from the FIRELIGHT-1 study (NCT04985604) on tovorafenib and its efficacy across solid tumors, and learn about challenges in treating acryl and mucosal melanoma from the IGNYTE trial (NCT03767348) of RP1 and a Phase II trial (NCT04493203) of nivolumab with axitinib.

The post Novel therapeutics in PD-1 refractory melanoma appeared first on VJOncology.

Climate Change and Other Environmental Factors on Lung Cancer Risk at WCLC 2024 Nov 08, 2024

Show notes

In this week’s podcast, we explore the critical links between environmental factors and lung cancer risk, focusing on the impacts of climate change, pollution, and exposure in conflict zones. Join us as we hear from experts Felipe Roitberg, MD, Brazilian Hospital Services Company (EBSERH), Brasília, Brazil, and Leticia Nogueira, MD, American Cancer Society, Palm Harbor, FL.

They share their insights from the IASLC 2024 World Conference on Lung Cancer (WCLC), highlighting the challenges and innovative solutions emerging from resource-scarce communities worldwide. Discover how climate change affects every stage of cancer care, from prevention to treatment, and the importance of addressing disparities in healthcare access.

The post Climate Change and Other Environmental Factors on Lung Cancer Risk at WCLC 2024 appeared first on VJOncology.

GI updates from ESMO 2024 Nov 04, 2024

Show notes

This week’s podcast from VJOncology brings you key updates in gastrointestinal cancer from the European Society of Medical Oncology (ESMO) 2024 annual meeting, which took place in Barcelona, Spain.

Hear from experts, Jessie Elliot (Trinity St. James’s Cancer Institute), Myriam Chalabi (Netherlands Cancer Institute), and Changhoon Yoo (Asan Medical Center) as they discuss the latest in biliary tract and colon cancers, as well as gastric and gastroesophageal junction adenocarcinoma. Highlights include findings from the TOPGEAR trial, extended follow-up results from the NICHE-2 and the NICHE-3 trials, as well as findings from the NIFTY and NALIRICC studies.

The post GI updates from ESMO 2024 appeared first on VJOncology.

Updates in the management of refractory colorectal cancer Oct 25, 2024

Show notes

In this week’s podcast, we bring you the latest developments in the field of refractory colorectal cancer. We are joined by Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain; Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany; Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy; and Cristina Smolenski, MD, Gustave Roussy, Villejuif, France.

We’ll hear about the current treatment landscape for refractory metastatic colorectal cancer, especially in the third-line settings, updates from the SOREGATT trial, which assessed regorafenib with chemotherapy in pretreated colorectal cancer, and the emerging role of fruquintinib, a selective VEGFR inhibitor, in patients who progress on regorafenib.

The post Updates in the management of refractory colorectal cancer appeared first on VJOncology.

ESSO 43 highlights Oct 11, 2024

Show notes

In this podcast, we bring you exclusive insights from the 43rd Congress of the European Society of Surgical Oncology (ESSO 43), held in Antwerp, Belgium. We will be joined by Isabel Rubio, MD, PhD (Vall d’Hebron University Hospital, Barcelona, Spain), who discusses the dual focus of modern cancer surgery and the transformative impact of robotic surgery; Sylvie Bonvalot, MD, PhD, HDR (Institut Curie, Paris, France), recipient of the ESSO Lifetime Achievement Award 2024, who reflects on her extensive experience with desmoid tumors and sarcoma surgery; and Mitsuru Sasako, MD, PhD (Yodogawa Christian Hospital, Osaka, Japan), recipient of the ESSO Gold Medal 2024, who shares remarkable cases in gastric cancer surgery.

We will hear about the latest advancements in surgical oncology, innovative techniques that enhance patient quality of life, and the significance of collaboration in the field. Additionally, we will discuss the evolution of treatment strategies for desmoid tumors and sarcomas, including active surveillance and limb salvage surgery, and the importance of personalized treatment approaches.

For more exclusive content on ESSO 43, visit VJOncology.com.

The post ESSO 43 highlights appeared first on VJOncology.

Highlights from ESMO 2024 Sep 20, 2024

Show notes

In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, Spain, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam, Netherlands; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London, UK; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany.

We’ll hear about final overall survival results from the Phase III KEYNOTE-522 trial (NCT03036488) of pembrolizumab in triple-negative breast cancer, updates from the Phase III NADINA trial (NCT04949113) of ipilimumab and nivolumab in melanoma, and findings from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in urothelial carcinoma, as well as the Phase III NIAGARA trial (NCT03732677) of neoadjuvant immunotherapy in muscle-invasive bladder cancer. Other highlights include data from the Phase III MARIPOSA-2 trial (NCT04487080) of amivantamab in EGFR-mutant lung cancer, the Phase III KEYNOTE-A18 (NCT04221945) study in cervical cancer, and the Phase III POD1UM-303 trial (NCT04472429) of retifanlimab in squamous cell anal carcinoma.

For more exclusive content on ESMO 2024, visit VJOncology.com.

The post Highlights from ESMO 2024 appeared first on VJOncology.

Latest updates in managing brain metastases Sep 11, 2024

Show notes

In this podcast, we bring you the latest insights into managing brain metastases, with expert commentary from Minesh Mehta, MD, Miami Cancer Institute, Miami, FL; Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL; Gaia Griguolo, MD, University of Padova, Padova, Italy; Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel; and Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China,.

We will cover key findings from the Phase III METIS trial (NCT02831959), which explored Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer and brain metastases. Other topics include the complexities of managing symptomatic brain metastases in melanoma, new advances in breast cancer treatment with anti-HER2 agents, and the role of radiotherapy in preserving cognitive function. Finally, we’ll discuss data from the DESTINY-Breast01, -02, and -03 trials (NCT03248492, NCT03523585, NCT03529110) on the CNS efficacy of trastuzumab deruxtecan (T-DXd).

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit VJOncology.com.

The post Latest updates in managing brain metastases appeared first on VJOncology.

Updates in immunotherapy for GU cancer Aug 23, 2024

Show notes

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat genitourinary cancer. This week we will be joined by Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

We will cover findings from key trials, including CHECKMATE 901 on nivolumab with gemcitabine and cisplatin for metastatic urothelial carcinoma; JAVELIN Renal 101 comparing avelumab plus axitinib with sunitinib for advanced renal cell carcinoma; a JAVELIN Bladder 100 post hoc analysis on avelumab for first-line maintenance in advanced urothelial carcinoma; TROPiCS-04 on sacituzumab govitecan in advanced urothelial carcinoma; and CheckMate 67T comparing subcutaneous and intravenous nivolumab for advanced renal cell carcinoma

For other GU cancer news, be sure to visit our dedicated GU Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

The post Updates in immunotherapy for GU cancer appeared first on VJOncology.

Advancements in precision medicine for colorectal cancer Aug 09, 2024

Show notes

In this week’s podcast, we will be covering recent updates and integrating precision medicine for the treatment of colorectal cancer. We’ll be covering a wide range of topics including biomarker-driven treatments, challenges in using minimal residual disease in the clinic and more.

Listen to expert insights from Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, Giulia Martini, University of Campania Luigi Vanvitelli, Naples, Italy, Paolo Manca, Memorial Sloan Kettering Cancer Center, New York, NY, and Eric Christensen, John Hopkins Medicine, Baltimore, MD, as they discuss hurdles and opportunities in precision medicine for colorectal cancer.

The post Advancements in precision medicine for colorectal cancer appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected